VRTX — Vertex Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $112.92bn
- $105.68bn
- $12.00bn
U.S. STOCKS ON THE MOVE-Energy stocks, Apple, Vertex
Vertex gets EU approval for next-generation cystic fibrosis drug; shares up
EU approves Vertex's next-generation cystic fibrosis drug (updated)
Vertex's next-generation cystic fibrosis drug gets EU approval
Brief: Vertex Announces European Commission Approval Of ALYFTREK, A New Once-Daily CFTR Modulator For The Treatment Of Cystic Fibrosis
Brief: Vertex And Ono Pharmaceutical Announce Strategic Agreement To Develop & Commercialize Povetacicept In Japan & South Korea
Brief: Vertex Pharmaceuticals Exec Says Cystic Fibrosis Portfolio Has About 9% Exposure To Medicare And About 23% Exposure To Medicaid - Goldman Sachs Conference
Eli Lilly to buy privately held SiteOne in deal worth up to $1 billion (updated)
Brief: Vertex Pharmaceuticals Inc - Authorizes $4 Billion Stock Repurchase Program - SEC Filing
U.S. STOCKS ON THE MOVE-Leidos, Gartner, EVgo
U.S. STOCKS ON THE MOVE-Duke Energy, Leidos, Gartner
Vertex Pharma falls after Q1 results miss
U.S. STOCKS ON THE MOVE-Datadog, Marriott, IQVIA
U.S. STOCKS ON THE MOVE-Gold miners, Eaton, Lemonade
Vertex Pharma falls after Q1 results miss
U.S. RESEARCH ROUNDUP-American Tower, GoDaddy, Labcorp
Vertex misses quarterly results on weaker-than-expected sales for cystic fibrosis drug (updated)
Vertex Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug